– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC –
– Combination has potential to address up to 50% of patients with HNSCC –
Read more at globenewswire.comKura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.